Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...

Revenue earned in the fourth quarter of 2024 was primarily the milestone revenue from Amgen and Novartis, as well as non-cash royalty revenue from Ultomiris and Monjuvi compared to the same period ...

Recent Partnership Developments Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen is advancing for the treatment of patients with prostate cancer. In the ...

Xencor anticipates selecting a lead candidate in 2025 and initiating first-in-human studies during 2026. Amgen: Xaluritamig is a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager that our partner Amgen ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab, exonerating the drugmakers' decision to press ahead with a regulatory filing despite a failed phase 3 trial.

Hyderabad: America's largest biotechnology company Amgen (AMGEN) launched its new technology and innovation site in Hyderabad on Monday. Chief Minister A Revanth Reddy and IT and Industries ...

Global biotech leader Amgen opened its $200 million technology and innovation centre in Hyderabad, a facility that will help the U.S. firm ramp up digital capabilities, open more opportunities for ...

Som Chattopadhyay, national executive India, Amgen, said the first 300 employees were hired within 78 days of signing the contract for the new facility and another 300 are to be onboarded soon ...